 Cabaletta Bio, Inc. CABA, a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the first quarter ended March 31, 2020. In May 2020, the Company announced that the U.S. Food and Drug Administration FDA granted Fast Track Designation to DSG3-CAART. 